The first approved PI3K inhibitor Idelalisib (Gilead Sciences, Inc., also known as CAL-101 and GS-1101), an orally bioavailable PI3Kδ selective inhibitor with high potency and selectivity (p110δ IC50 = 2.5 nM), was approved by the FDA in July 2014 for the treatment of several hematological malignancies, in combination with rituximab. The gene discussed is PIK3CD; the disease is hematologic disorder.